| Stereochemistry | RACEMIC |
| Molecular Formula | C15H19N3O5 |
| Molecular Weight | 321.3285 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(COC(N)=O)C1=C(N2CC2)C(=O)C(C)=C(N3CC3)C1=O
InChI
InChIKey=SHHKQEUPHAENFK-UHFFFAOYSA-N
InChI=1S/C15H19N3O5/c1-8-11(17-3-4-17)14(20)10(9(22-2)7-23-15(16)21)12(13(8)19)18-5-6-18/h9H,3-7H2,1-2H3,(H2,16,21)
| Molecular Formula | C15H19N3O5 |
| Molecular Weight | 321.3285 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Carboquone (CQ) is an anticancer alkylating agent synthesized and developed by Arakawa et al. (Sankyo Co, Ltd.) in 1970, having chemical structure, 2,5-bis-(1-aziridinyl)-3-(2-carbamoyloxy-1-methoxyethyl)-6-methyl- 1,4- benzoquinone. The antitumor efficacies of CQ were reported as excellent, however, the side effects are considerably strong. Carboquone is used to treat various forms of cancer. It is indicated for the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Oral Chronic myeloid leukaemia
Adult: Initial doses for remission induction: 1-2 mg daily.
Maintenance: 0.25-0.75 mg every other day or twice wkly; adjust dose to maintain WBC count between 8000 and 15000/mm 3. Doses may vary depending on regimens.
Oral Cancer chemotherapy
Adult: 1-1.5 mg daily in 2-3 divided doses.
Route of Administration:
Oral
